HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer

BACKGROUND: Patients with metastatic colorectal cancer (mCRC) harboring wild-type KRAS benefit from epidermal growth factor receptor (EGFR)-targeted therapy. However, patients who are treated with anti-EGFR antibodies will eventually develop the resistance to those agents. HER2 amplification is one...

Descripción completa

Detalles Bibliográficos
Autores principales: Takegawa, Naoki, Yonesaka, Kimio, Sakai, Kazuko, Ueda, Hiroto, Watanabe, Satomi, Nonagase, Yoshikane, Okuno, Tatsuya, Takeda, Masayuki, Maenishi, Osamu, Tsurutani, Junji, Satoh, Taroh, Okamoto, Isamu, Nishio, Kazuto, Tamura, Takao, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823119/
https://www.ncbi.nlm.nih.gov/pubmed/26657506
http://dx.doi.org/10.18632/oncotarget.6498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4823119/
https://www.ncbi.nlm.nih.gov/pubmed/26657506
http://dx.doi.org/10.18632/oncotarget.6498

Ejemplares similares